Cost-effectiveness analysis between sodium valproate and levetiracetam in the treatment of childhood epilepsy
10.12206/j.issn.2097-2024.202408046
- VernacularTitle:丙戊酸钠与左乙拉西坦治疗儿童癫痫病的成本-效果分析
- Author:
Wei SHAO
1
;
Ni YUAN
2
;
Ye LIU
3
;
Fei YU
1
;
Ying LIU
1
;
Feng WANG
1
Author Information
1. Liaoning Medical Vocational College, Shenyang 110101, China.
2. Dalian Medical University, Dalian 116044, China.
3. The Ninth People’s Hospital of Shenyang, Shenyang 110024, China.
- Publication Type:Pharmacyadministration
- Keywords:
valproate;
levetiracetam;
childhood epilepsy;
cost-effectiveness analysis
- From:
Journal of Pharmaceutical Practice and Service
2025;43(8):410-413
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the cost-effectiveness between sodium valproate and levetiracetam in the treatment of childhood epilepsy and provide an economic basis for clinical medication choices. Methods A cost-effectiveness analysis was conducted using a decision tree model to compare the effectiveness and drug costs of sodium valproate and levetiracetam in treating childhood epilepsy. Single-factor sensitivity analysis and probabilistic sensitivity analysis were used to assess the impact of parameter variations on the study results. Results The treatment cost of levetiracetam was significantly higher than that of sodium valproate. The incremental cost-effectiveness ratio （ICER） of levetiracetam compared to sodium valproate was ¥8 628.43. Sensitivity analysis results were consistent with the base-case analysis. The probabilistic sensitivity analysis showed that, over a 6-month treatment period, levetiracetam became a more cost-effective option when the willingness-to-pay （WTP） threshold was ¥9,000 or higher. One-way sensitivity analysis revealed that the price of levetiracetam was the most influential factor affecting the ICER. Conclusion When the WTP per effective pediatric epilepsy case is ¥9,000 or higher, levetiracetam demonstrates a cost-effectiveness advantage.
